CN104815334A - Combined living vaccine dilute solution for swine transmissible gastroenteritis and epidemic diarrhea - Google Patents
Combined living vaccine dilute solution for swine transmissible gastroenteritis and epidemic diarrhea Download PDFInfo
- Publication number
- CN104815334A CN104815334A CN201510184521.1A CN201510184521A CN104815334A CN 104815334 A CN104815334 A CN 104815334A CN 201510184521 A CN201510184521 A CN 201510184521A CN 104815334 A CN104815334 A CN 104815334A
- Authority
- CN
- China
- Prior art keywords
- solution
- liquid
- transmissible gastroenteritis
- epidemic diarrhea
- oil phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a vaccine dilute solution, in particular to a combined living vaccine dilute solution for swine transmissible gastroenteritis and epidemic diarrhea. The combined living vaccine dilute solution comprises a solution A and a solution B, the solution A per litter comprises 8g of NaCl (Sodium Chloride), 0.2g of KCl (Potassium Chloride), 3.58g of Na2HPO4. 12H2O (Disodium Hydrogen Phosphate) and 0.24g of KH2PO4 (Mono-potassium Phosphate), the solution B is further added with astragalus polysaccharide, propolis, Tween-80 and mineral oil, in addition to materials in the solution A, and the solution A and the solution B are uniformly mixed according to the mass ratio of 1:1. According to the combined living vaccine dilute solution for swine transmissible gastroenteritis and epidemic diarrhea provided by the invention, the vaccine immunity effect can be improved, and the swinery can obtain better immune protection force.
Description
Technical field
The present invention relates to a kind of live vaccine diluent, especially transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine diluent.
Background technology
Porcine epizootic diarrhea and transmissible gastroenteritis of swine are worldwide widely current, especially in Korea S, and the Asian countries such as Japan and China.It has carried out economic loss seriously to industrial belt of raising pigs.PED causes that the survival rate of pig reduces, regularity is poor, slows down the speed of growth, weightening finish reduces, postpone Time To Market, reduce efficiency of feed utilization, increase and additionally consume, reduce domestic animal premunition, increase susceptibility to antibacterial, virus, increase sickness rate, improves medical expense, domestic animal dehydration, shock, dead, pig have loose bowels the serious consequences such as weight loss.
At present, for porcine epizootic diarrhea and transmissible gastroenteritis of swine also without definite effective Therapeutic Method, therefore to the prevention and control of these two kinds of diseases, the policy adopting " put prevention first, support anti-combination " more.In order to effectively control porcine epizootic diarrhea and transmissible gastroenteritis of swine, China has developed the vaccine for preventing and treating porcine epizootic diarrhea and transmissible gastroenteritis of swine, but to its diluent, particularly be applicable to transmissible gastroenteritis of swine simultaneously, the research of epidemic diarrhea bigeminal live vaccine diluent is less, currently available vaccines, existing vaccines diluent effect is not good for the effect of transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine yet.
Summary of the invention
For above-mentioned technical problem, the invention provides a kind of transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine diluent, can immune effect of vaccine be improved, make swinery obtain better immune protective efficiency.Concrete technical scheme is:
Transmissible gastroenteritis of swine, epidemic diarrhea live vaccine diluent, prepare gained by following steps:
(1) A liquid preparation
Containing the Na of KCl, 3.58g of NaCl, 0.2g of 8g in often liter of A liquid
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves, in water for injection, carries out sterilization treatment under 121 DEG C of temperature, 100 kPas of pressure conditions;
(2) B liquid preparation
Aqueous phase: the Na of KCl, the 3.58g of NaCl, 0.2g containing 8g in every premium on currency
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves is in water for injection; Add astragalus polysaccharides, propolis, Tween 80 again, adding rear astragalus polysaccharides concentration is 0.5 ~ 5%w/v, and propolis concentration is 10 ~ 100mg/ml, and Tween 80 concentration is 1 ~ 5%w/v, for subsequent use after filtration sterilization;
Oil phase: for subsequent use after 121 DEG C, mineral oil, 100 kPas of pressure sterilizings;
Oil phase slowly to be added in aqueous phase and to stir, oil phase and aqueous phase weight ratio 1: 2, re-using high-shear emulsion machine after oil phase adds and obtain B liquid with 4000r/min emulsifying 30min;
(3) use of diluent: during use, A liquid and B liquid to be mixed homogeneously in mass ratio at 1: 1.
Transmissible gastroenteritis of swine provided by the invention, epidemic diarrhea bigeminal live vaccine diluent, can improve immune effect of vaccine, makes swinery obtain better immune protective efficiency.
Accompanying drawing explanation
Fig. 11 ~ 3 age in days piglet TGE NAT;
Fig. 21 ~ 3 age in days piglet PED NAT;
Fig. 3 sow TGE NAT;
Fig. 4 sow PED NAT.
Detailed description of the invention
The specific embodiment of the present invention is described in conjunction with the embodiments.
Transmissible gastroenteritis of swine, epidemic diarrhea live vaccine diluent, prepare gained by following steps:
(1) A liquid preparation
Containing the Na of KCl, 3.58g of NaCl, 0.2g of 8g in often liter of A liquid
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves, in water for injection, carries out sterilization treatment under 121 DEG C of temperature, 100 kPas of pressure conditions;
(2) B liquid preparation
Aqueous phase: the Na of KCl, the 3.58g of NaCl, 0.2g containing 8g in every premium on currency
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves is in water for injection; Add astragalus polysaccharides, propolis, Tween 80 again, adding rear astragalus polysaccharides concentration is 0.5 ~ 5%w/v, and propolis concentration is 10 ~ 100mg/ml, and Tween 80 concentration is 1 ~ 5%w/v, for subsequent use after filtration sterilization;
Oil phase: for subsequent use after 121 DEG C, mineral oil, 100 kPas of pressure sterilizings;
Oil phase slowly to be added in aqueous phase and to stir, oil phase and aqueous phase weight ratio 1: 2, re-using high-shear emulsion machine after oil phase adds and obtain B liquid with 4000r/min emulsifying 30min;
(3) use of diluent: during use, A liquid and B liquid to be mixed homogeneously in mass ratio at 1: 1.
The diluent of above embodiment gained and comparison example are carried out contrast experiment:
1, vaccine dilution: transmissible gastroenteritis, epidemic diarrhea bigeminal live vaccine are diluted to 1 part/ml by the diluent using the present embodiment to obtain, phosphate buffer PBS respectively.
2, immunity contrast
(1) 1 ~ 3 age in days piglet: 1 ~ 3 age in days piglet 15, is divided into A1, B1, C13 group, often organizes 5.
Vaccine after the diluted that the existing the present embodiment of A1 group injection obtains, 1.0ml/ head; Vaccine after B1 group injection PBS dilution, 1.0ml/ head; PBS is as blank group for the injection of C1 group, 1.0ml/ head.0th, 7,14,21,28 and 35 day separation of serum of taking a blood sample respectively after immunity, measures PED and TGE NAT, calculates the geometrical mean of often group piglet antibody titer and carries out comparative analysis.
(2) sow: antenatal 28 ~ 35 age in days sow 15, is divided into A2, B2, C23 group, often organizes 5.Vaccine after the diluted that A2 group group injection embodiment obtains; Vaccine after B2 group injection PBS dilution, 1.0ml/ head; PBS is as blank group for the injection of C2 group, 1.0ml/ head.After immunity, the 0th, 14,28,35 take a blood sample separation of serum respectively, measure PED and TGE NAT, calculate the geometrical mean of often organizing sow antibody titer and carry out comparative analysis.
3, interpretation of result
(1) 1 ~ 3 age in days piglet: diluent group 1 ~ 3 age in days TGE antibody horizontal that the 7th, 14,21,28 and 35 day produces after immunity is apparently higher than PBS group and blank group; The PED antibody horizontal that after immunity, the 7th, 14,21,28 and 35 day produces is apparently higher than PBS group and blank group, and the 7th day diluent group PED antibody titer geometrical mean, higher than 1: 32, the results are shown in Figure 1 and Fig. 2 after vaccine immunity.
(2) sow: after the immunity of diluent group sow the 14th, 28,35 and produce the same day TGE antibody horizontal apparently higher than PBS group and blank group; After immunity, the 14th, 28 and 35 day PED antibody horizontal is apparently higher than PBS group and matched group, the results are shown in Figure 3 and Fig. 4.Sow PED and TGE High antibody level, contribute to primiparity piglet and obtain protection by maternal antibody, thus reduce or to alleviate the disease caused by transmissible gastroenteritis or epidemic diarrhea even dead.
Claims (1)
1. transmissible gastroenteritis of swine, epidemic diarrhea live vaccine diluent, is characterized in that, prepare gained by following steps:
(1) A liquid preparation
Containing the Na of KCl, 3.58g of NaCl, 0.2g of 8g in often liter of A liquid
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves, in water for injection, carries out sterilization treatment under 121 DEG C of temperature, 100 kPas of pressure conditions;
(2) B liquid preparation
Aqueous phase: the Na of KCl, the 3.58g of NaCl, 0.2g containing 8g in every premium on currency
2hPO
412H
2the KH of O, 0.24g
2pO
4, above substance dissolves is in water for injection; Add astragalus polysaccharides, propolis, Tween 80 again, adding rear astragalus polysaccharides concentration is 0.5 ~ 5%w/v, and propolis concentration is 10 ~ 100mg/ml, and Tween 80 concentration is 1 ~ 5%w/v, for subsequent use after filtration sterilization;
Oil phase: for subsequent use after 121 DEG C, mineral oil, 100 kPas of pressure sterilizings;
Oil phase slowly to be added in aqueous phase and to stir, oil phase and aqueous phase weight ratio 1: 2, re-using high-shear emulsion machine after oil phase adds and obtain B liquid with 4000r/min emulsifying 30min;
(3) use of diluent: during use, A liquid and B liquid to be mixed homogeneously in mass ratio at 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510184521.1A CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510184521.1A CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104815334A true CN104815334A (en) | 2015-08-05 |
| CN104815334B CN104815334B (en) | 2017-09-26 |
Family
ID=53725966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510184521.1A Active CN104815334B (en) | 2015-04-17 | 2015-04-17 | Transmissible gastroenteritis of swine, epidemic diarrhea bigeminal live vaccine dilution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104815334B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474246A (en) * | 2009-01-23 | 2009-07-08 | 北京伟嘉人生物技术有限公司 | Pharmaceutical composition for enhancing immunity of fowl and coordinating with vaccine for synergy |
| CN101690809A (en) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | Propolis-astragalus polysaccharides compound nanometer emulsion adjuvant and preparation method and application thereof |
| CN102406936A (en) * | 2011-11-22 | 2012-04-11 | 青岛易邦生物工程有限公司 | Chicken infectious coryza inactivated vaccine adjuvant |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
-
2015
- 2015-04-17 CN CN201510184521.1A patent/CN104815334B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474246A (en) * | 2009-01-23 | 2009-07-08 | 北京伟嘉人生物技术有限公司 | Pharmaceutical composition for enhancing immunity of fowl and coordinating with vaccine for synergy |
| CN101690809A (en) * | 2009-09-30 | 2010-04-07 | 西北农林科技大学 | Propolis-astragalus polysaccharides compound nanometer emulsion adjuvant and preparation method and application thereof |
| CN102406936A (en) * | 2011-11-22 | 2012-04-11 | 青岛易邦生物工程有限公司 | Chicken infectious coryza inactivated vaccine adjuvant |
| CN104147599A (en) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | Vaccine adjuvant as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104815334B (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432578B (en) | Preparation method of C-type clostridium perfringens toxin vaccine of piglet red dysentery | |
| CN102086447A (en) | Duck virus hepatitis strains and inactivated vaccine | |
| CN106540248A (en) | A kind of vaccine combination of resistant to foot and mouth disease and its preparation method and application | |
| CN103820397A (en) | Muscovy duck parvovirus and application thereof | |
| CN102743750B (en) | Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent | |
| CN103083659A (en) | Preparation method and application of novel oil-free adjuvant | |
| CN103768594A (en) | Traditional Chinese medicine mulberry polysaccharide and eucommia polysaccharide immunopotentiator and application thereof | |
| CN104740623A (en) | Preparation method for swine escherichia coli disease inactivated vaccine | |
| CN102793920B (en) | Compound immunopotentiator, inactivated vaccine for poultry, and preparation method thereof | |
| CN104815334A (en) | Combined living vaccine dilute solution for swine transmissible gastroenteritis and epidemic diarrhea | |
| CN101374547A (en) | Vaccine for in ovo inoculation | |
| CN102716479A (en) | Pig breeding and respiratory syndrome NVDC-JXA1 strain-porcine parvovirus disease duplex inactivated vaccine and preparation method and application thereof | |
| CN108379575A (en) | A kind of inactivated vaccine and preparation method thereof prepared with newcastle disease virus thermostabilization strain | |
| CN104667269A (en) | nasal immune vaccine for porcine epizootic diarrhea virus and preparation method of immune vaccine | |
| CN103834620B (en) | NDV, ewcastle disease inactivated vaccine and preparation method thereof | |
| CN103948622B (en) | Sensor Chip CM 5 improves the application in avian influenza vaccine antibody positive rate medicine in preparation | |
| CN102631675B (en) | High-efficiency CpG preparation, preparation method thereof and application | |
| CN108014333B (en) | Mucosal targeted immunopotentiator for animals and application thereof in veterinary vaccines | |
| CN103157104B (en) | The sodium thiosulfate diluent of swine Fever Vaccine | |
| CN102321180B (en) | Polypeptide fragment composition and application in preparation of porcine reproductive and respiratory syndrome vaccine thereof | |
| CN103690951B (en) | A kind of preparation method of water resistant ermine Pseudomonas aeruginosa pneumonia veterinary drug | |
| CN105031645B (en) | A kind of Antirabic Vaccine and preparation method thereof | |
| CN104623653A (en) | Vaccine composition and preparation method thereof | |
| CN103705935A (en) | Heat-proof freeze-dried protective agent and preparation method and application thereof | |
| CN103169978B (en) | Temperature control slow release injection for bird immune globulin as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 641400 Shipan Food and Pharmaceutical Industrial Park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee after: HUAPAI BIOENGINEERING GROUP CO.,LTD. Address before: 641402 Food and Pharmaceutical Industrial Park, Shipan Economic Development Zone, Jianyang City, Ziyang City, Sichuan Province Patentee before: SICHUAN HUAPAI BIO-PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 641400 Shipan food and pharmaceutical industrial park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee after: Huapai Biotechnology (Group) Co.,Ltd. Address before: 641400 Shipan food and pharmaceutical industrial park, Jianyang Economic Development Zone, Ziyang City, Sichuan Province Patentee before: HUAPAI BIOENGINEERING GROUP CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder |